Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.50 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | CASP2 | P42575 | 1/20 | 0.43 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.43 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28757328 | 0.85 | PRMT1 (0.68) | TSHRLMNAEPHX2PRMT1ADRA1A | |
| SCHEMBL3280998 | 0.85 | PRMT1 (0.50) | TSHRLMNAEPHX2PRMT1ADRA1A | |
| SCHEMBL15399971 | 0.84 | TSHR (0.65) | TSHRLMNAEPHX2PRMT1ADRA1A | |
| SCHEMBL8766995 | 0.82 | PRMT1 (0.71) | TSHRLMNAEPHX2PRMT1ADRA1A | |
| SCHEMBL11468363 | 0.82 | PRMT1 (0.71) | TSHRLMNAEPHX2PRMT1ADRA1A | |
| SCHEMBL24483715 | 0.82 | PRMT1 (0.71) | TSHRLMNAEPHX2PRMT1ADRA1A | |
| SCHEMBL17767810 | 0.82 | PRMT1 (0.71) | TSHRLMNAEPHX2PRMT1ADRA1A | |
| SCHEMBL22506195 | 0.82 | PRMT1 (0.71) | TSHRLMNAEPHX2PRMT1ADRA1A | |
| SCHEMBL19646468 | 0.82 | PRMT1 (0.71) | TSHRLMNAEPHX2PRMT1ADRA1A | |
| SCHEMBL8507619 | 0.82 | PRMT1 (0.71) | TSHRLMNAEPHX2PRMT1ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4559528-A2 | ENHANCED LOADING OF INTACT, BACTERIALLY DERIVED VESICLES WITH SMALL MOLECULE COMPOUNDS | EnGeneIC Molecular Delivery Pty Ltd. (AU) | 2025-05-28 | — | — | EP | disclosed |
| CN-106999444-B | Enhanced loading of small molecule compounds with intact bacterially derived vesicles | 安吉尼科分子传输公司 | 2023-12-12 | — | — | CN | disclosed |
| US-11052157-B2 | Enhanced loading of intact, bacterially derived vesicles with small molecule compounds | ENGENEIC MOLECULAR DELIVERY PTY LTD. (AU) | 2021-07-06 | — | — | US | disclosed |
| US-20190216946-A1 | ENHANCED LOADING OF INTACT, BACTERIALLY DERIVED VESICLES WITH SMALL MOLECULE COMPOUNDS | ENGENELC MOLECULAR DELIVERY PTY LTD (AU) | 2019-07-18 | — | — | US | disclosed |
| US-10328159-B2 | Enhanced loading of intact, bacterially derived vesicles with small molecule compounds | ENGENIC MOLECULAR DELIVERY PTY LTD. (AU) | 2019-06-25 | — | — | US | disclosed |
| EP-3200765-A1 | ENHANCED LOADING OF INTACT, BACTERIALLY DERIVED VESICLES WITH SMALL MOLECULE COMPOUNDS | EnGeneIC Molecular Delivery Pty Ltd (AU) | 2017-08-09 | — | — | EP | disclosed |
| US-20160095941-A1 | ENHANCED LOADING OF INTACT, BACTERIALLY DERIVED VESICLES WITH SMALL MOLECULE COMPOUNDS | ENGENEIC MOLECULAR DELIVERY PTY LTD. (AU) | 2016-04-07 | — | — | US | disclosed |
| WO-2016051389-A1 | ENHANCED LOADING OF INTACT, BACTERIALLY DERIVED VESICLES WITH SMALL MOLECULE COMPOUNDS | ENGENEIC MOLECULAR DELIVERY PTY LTD (AU) | 2016-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11052157-B2 | Enhanced loading of intact, bacterially derived vesicles with small molecule compounds | EXOSC10, EXOSC5, EXOSC4 | TSHR 4815/4885LMNA 3877/4885EPHX2 4207/4885 |
| US-20190216946-A1 | ENHANCED LOADING OF INTACT, BACTERIALLY DERIVED VESICLES WITH SMALL MOLECULE COMPOUNDS | EXOSC10, EXOSC5, EXOSC4 | TSHR 4815/4885LMNA 3877/4885EPHX2 4207/4885 |
| US-20160095941-A1 | ENHANCED LOADING OF INTACT, BACTERIALLY DERIVED VESICLES WITH SMALL MOLECULE COMPOUNDS | EXOSC10, EXOSC5, EXOSC4 | TSHR 4815/4885LMNA 3877/4885EPHX2 4207/4885 |
| US-10328159-B2 | Enhanced loading of intact, bacterially derived vesicles with small molecule compounds | EXOSC10, EXOSC5, EXOSC4 | TSHR 4815/4885LMNA 3877/4885EPHX2 4207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.